Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design

Yusha Wang,Jun Wang,Wenjie Zheng,Jiahui Zhang,Jinbo Wang,Taijie Jin,Panfeng Tao,Yibo Wang,Chenlu Liu,Jiqian Huang,Pui Y Lee,Xiaomin Yu,Qing Zhou,Pui Y. Lee

DOI: https://doi.org/10.1016/j.immuni.2023.05.014

IF: 32.4

2023-06-01

Immunity

Abstract:The interleukin 1 (IL-1) pathway signals through IL-1 receptor type 1 (IL-1R1) and emerges as a central mediator for systemic inflammation. Aberrant IL-1 signaling leads to a range of autoinflammatory diseases. Here, we identified a de novo missense variant in IL-1R1 (p.Lys131Glu) in a patient with chronic recurrent multifocal osteomyelitis (CRMO). Patient PBMCs showed strong inflammatory signatures, particularly in monocytes and neutrophils. The p.Lys131Glu substitution affected a critical positively charged amino acid, which disrupted the binding of the antagonist ligand, IL-1Ra, but not IL-1α or IL-1β. This resulted in unopposed IL-1 signaling. Mice with a homologous mutation exhibited similar hyperinflammation and greater susceptibility to collagen antibody-induced arthritis, accompanied with pathological osteoclastogenesis. Leveraging the biology of the mutation, we designed an IL-1 therapeutic, which traps IL-1β and IL-1α, but not IL-1Ra. Collectively, this work provides molecular insights and a potential drug for improved potency and specificity in treating IL-1-driven diseases.

immunology

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve

This paper aims to address the issue of autoinflammatory diseases caused by mutations in the IL-1 receptor (IL-1R1) and to develop new drugs targeting IL-1 based on this.

Specifically:
- **Mutation Identification**: The paper first identifies a new missense mutation (p.Lys131Glu) located in the IL-1 receptor (IL-1R1), which leads to an autoinflammatory disease known as Chronic Recurrent Multifocal Osteomyelitis (CRMO).
- **Mutation Impact**: This mutation makes IL-1R1 insensitive to the antagonist IL-1Ra, resulting in continuous IL-1 signaling.
- **Therapeutic Strategy**: Based on this discovery, the researchers designed a more specific and effective IL-1 targeting drug that can capture IL-1β and IL-1α but not IL-1Ra.

Through these studies, the paper provides new molecular insights into the treatment of IL-1-driven autoinflammatory diseases and proposes potential new drug design strategies.